Source:http://linkedlifedata.com/resource/pubmed/id/20640910
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0021760,
umls-concept:C0030705,
umls-concept:C0078058,
umls-concept:C0081487,
umls-concept:C0087111,
umls-concept:C0175630,
umls-concept:C0243077,
umls-concept:C0331858,
umls-concept:C0439234,
umls-concept:C0439810,
umls-concept:C0441889,
umls-concept:C0812246,
umls-concept:C0949690,
umls-concept:C1171892,
umls-concept:C1456820,
umls-concept:C1704640,
umls-concept:C1706515,
umls-concept:C1954261
|
pubmed:issue |
11
|
pubmed:dateCreated |
2010-9-21
|
pubmed:abstractText |
The objectives of the study were to investigate short and long-term changes and relations to treatment response of plasma interleukin-6 (IL-6), vascular endothelial growth factor (VEGF), YKL-40, matrix metalloproteinase-3 (MMP-3), and total aggrecan in patients with spondyloarthritis (SpA) treated with tumor necrosis factor-alpha (TNF?) inhibitors and to compare with levels in healthy subjects. Biomarkers were measured in an observational cohort of 49 SpA patients (ankylosing spondylitis, n=32, and psoriatic arthritis, n=17) initiating TNF? inhibitor therapy (infliximab, n=38; etanercept, n=8; and adalimumab, n=3) and compared with levels in healthy subjects. Clinical parameters and biomarkers were measured at baseline, weeks 2, 6, and every 6-12 weeks for up to 3 years. Patients with co-morbidities (n=4), missing baseline samples (n=3), and adverse events (n=5) were excluded. Patients with SpA had compared with healthy subjects elevated IL-6 (median 8.5 ng/l (range, 0.98-64) vs. 1.3 (0.33-26)), VEGF (105 ng/l (22-752) vs. 45 (12-351)), YKL-40 (74 ?g/l (14-572) vs. 43 (20-184)), and MMP-3 (43 ?g/l (9.1-401) vs. 16 (2.5-47), p?0.001), whereas total aggrecan was lower (662 ?g/l (223-2,219) vs. 816 (399-2,190), p?0.001). Two weeks after first treatment, all biomarker levels changed towards normal levels (p?0.03) in clinical responders (n=24), and persistent reductions over 3 years were found in IL-6, VEGF, YKL-40, and MMP-3. Only MMP-3 decreased (p?0.02) in non-responders (n=13). The study demonstrated changes of plasma IL-6, VEGF, YKL-40, MMP-3, and total aggrecan and a potential value for monitoring disease activity and treatment response in SpA patients. Larger prospective studies are required to clarify clinical utility of these biomarkers.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adipokines,
http://linkedlifedata.com/resource/pubmed/chemical/Aggrecans,
http://linkedlifedata.com/resource/pubmed/chemical/Biological Markers,
http://linkedlifedata.com/resource/pubmed/chemical/CHI3L1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Glycoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-6,
http://linkedlifedata.com/resource/pubmed/chemical/Lectins,
http://linkedlifedata.com/resource/pubmed/chemical/Matrix Metalloproteinase 3,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/Vascular Endothelial Growth Factor A
|
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
1434-9949
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
29
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1301-9
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:20640910-Adipokines,
pubmed-meshheading:20640910-Adult,
pubmed-meshheading:20640910-Aged,
pubmed-meshheading:20640910-Aggrecans,
pubmed-meshheading:20640910-Biological Markers,
pubmed-meshheading:20640910-Cohort Studies,
pubmed-meshheading:20640910-Female,
pubmed-meshheading:20640910-Gene Expression Regulation,
pubmed-meshheading:20640910-Glycoproteins,
pubmed-meshheading:20640910-Humans,
pubmed-meshheading:20640910-Interleukin-6,
pubmed-meshheading:20640910-Lectins,
pubmed-meshheading:20640910-Male,
pubmed-meshheading:20640910-Matrix Metalloproteinase 3,
pubmed-meshheading:20640910-Middle Aged,
pubmed-meshheading:20640910-Spondylarthritis,
pubmed-meshheading:20640910-Tumor Necrosis Factor-alpha,
pubmed-meshheading:20640910-Vascular Endothelial Growth Factor A
|
pubmed:year |
2010
|
pubmed:articleTitle |
Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNF? inhibitors.
|
pubmed:affiliation |
Department of Rheumatology, Copenhagen University Hospital, Herlev and Gentofte, Denmark. susanne_juhl_ped@dadlnet.dk
|
pubmed:publicationType |
Journal Article
|